<DOC>
	<DOCNO>NCT02300311</DOCNO>
	<brief_summary>To evaluate efficacy Finalgon® cream ( 1.08 % Nicoboxil/ 0.17 % Nonivamide ) versus placebo patient acute low back pain . To investigate safety tolerability repeat use Finalgon® cream ( 1.08 % Nicoboxil/ 0.17 % Nonivamide ) .</brief_summary>
	<brief_title>Efficacy Safety Finalgon® Cream Multiple Doses Acute Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Nonivamide</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must sign date Informed Consent consistent International Conference Harmonisation ( ICH ) /Good Clinical Practice ( GCP ) guideline local regulation prior participation trial . 2 . Patients must agree cooperate trial evaluation perform require task . 3 . Patients must acute nonspecific low back pain , ICD10 code : M54.5 . 4 . Patients must acute low back pain 2 day less 21 day ( = 3 week ) . 5 . Male female equal 18 less equal 65 year age Visit 1 ( Baseline ) . 6 . Low back pain Pain intensity equal 5 010 numerical rating scale ( NRS ) . Exclusion criterion : 1 . Patients significant disease acute nonspecific low back pain . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial . 2 . Multilocular pain panalgesia . 3 . History 3 low back pain episode last 6 month . 4 . Acute low back pain due vertebral collapse neoplastic , inflammatory ( ankylose spondylitis ) , traumatic , infective origin . 5 . Abnormal finding least one follow assessment : Achilles tendon reflex , patella reflex , heel walking , toe walking , cutaneous sensitivity leg ( include gluteal region ) , paresis test supine position upon dorsiflexion , plantarflexion , hip flexion , knee extension . 6 . Neurogenic Bladder and/or rectum dysfunction . 7 . Any condition , disease concomitant treatment judgement investigator affect patient 's ability participate clinical trial influence trial methodology use . 8 . Negative experience past heat treatment muscle complaint ( e. g. hot water bottle , heat pad , hyperemisationinducing topical cream , ointment patch ) . 9 . Patients history treatment back pain centrally act drug ( e.g . opioids ) muscle relaxant within 6 month prior enrolment . 10 . Surgery due back pain rehabilitation due back pain last 12 month . 11 . Spinal injection back pain treatment within 6 month prior enrolment . 12 . Intake antidepressant/antipsychotic medication within 4 week prior enrolment . 13 . Treatment recent low back pain period oral analgesic 4 consecutive day . 14 . Locally apply medication back within 24 hour prior enrolment ( topical treatment , injection ) . 15 . Nonpharmacological low back pain treatment ( physiotherapy , heat treatment [ e.g . hot water bottle , heat patch ] , massage ) within 12 hour prior enrolment . 16 . Administration analgesic within 12 h prior enrolment ( exception : acetylsalicylic acid [ ASS ] 100 mg/daily antiplateletaggregation therapy ) . 17 . Nonpharmacological low back pain treatment ( physiotherapy , heat treatment [ e.g . hot water bottle , heat patch ] , massage ) within 12 hour prior enrolment . 18 . Participation investigational drug device trial within 4 week prior enrolment . 19 . History treatment back pain centrally act drug ( e.g . opioids ) muscle relaxant . 20 . Treatment recent low back pain period oral analgesic 4 consecutive day . 21 . Surgery due back pain rehabilitation due back pain last 12 month . 22 . Spinal injection back pain treatment within 6 month prior enrolment . 23 . Intake antidepressant/antipsychotic medication within 4 week prior enrolment . 24 . Known hypersensitivity nicoboxil , nonivamide , ingredient cream . 25 . Known hypersensitivity paracetamol . 26 . Skin lesion ( e.g . rash , bruising , laceration ) back region . 27 . Known history central nervous system disease severe intellectual memory disorder , psychiatric disorder . 28 . History abuse alcohol/drugs within six month prior enrolment . 29 . Acute relapse chronic kidney disease . 30 . Severe hepatocellular insufficiency . 31 . Pregnant nursing woman , include female patient positive ßHCG test Visit 1 . 32 . Female patient childbearing potential use highly effective method birth control . 33 . Patients currently participate another trial participate another trial within one month prior Visit 1 , patient previously randomise trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>